THYNTRA THERAPEUTICS
Live / Applied — Non-final action mailed (as of 28 Mar 2026)
What this means for you
Not registered yet, but its 24 Nov 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99512500
- Mark type
- Stylized text
- Filed
- 24 Nov 2025
- Attorney of record
- Jessica R Manganello
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Pharmaceutical preparations for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Biological preparations for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Biologics in the nature of pharmaceutical preparations for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Biological preparations for the prevention and treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Diagnostic preparations for in vitro testing for medical use; Antibody reagents used for the detection of antigens in cells and tissue for medical purposes; Medical diagnostic reagents; Diagnostic reagents for medical use; Diagnostic agents, preparations and substances for medical purposes; Medical diagnostic reagents for use in detection, diagnosis, patient stratification, and treatment monitoring for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Diagnostic reagents for medical purposes for use in detection, diagnosis, patient stratification, and treatment monitoring for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Antibodies for medical purposes; Therapeutic antibodies for human use for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Pharmaceutical preparations for gene therapy for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Drug delivery agents in the form of intranasal spray (nasal sprays), inhalation (aerosols and dry powers), oral (tables, capsules, liquids), topical (creams, gels, transdermal patches), intravenous, and intrathecal routes that facilitate the delivery of pharmaceutical preparations; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Clinical medical reagents; Diagnostic kits comprising diagnostic agents, preparations and substances for medical purposes
Owner
- Cogthera, LLC, Brookeville, MD, US
Prosecution history
- 28 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 28 Mar 2026 — NON-FINAL ACTION E-MAILED
- 28 Mar 2026 — NON-FINAL ACTION WRITTEN
- 28 Mar 2026 — ASSIGNED TO EXAMINER
- 24 Nov 2025 — APPLICATION FILING RECEIPT MAILED
- 24 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 24 Nov 2025 — NEW APPLICATION ENTERED